文献速递心律失常血脂与心血管预防

长期补充海洋ω-3脂肪酸与房颤风险:心血管结局随机试验的系统评价与荟萃分析

Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.
PubMed 文献 · Circulation · 2021-10-06

结果显示补充海洋ω-3脂肪酸与房颤风险增加相关(HR 1.25,95%CI 1.07-1.46),且剂量>1 g/d的试验风险更高(HR 1.49),荟萃回归显示每增加1 g/d剂量房颤风险增加(HR 1.11)。

要点

  • 补充海洋ω-3脂肪酸与房颤风险增加相关,HR 1.25(95%CI 1.07-1.46)。
  • 剂量>1 g/d的试验房颤风险更高(HR 1.49),≤1 g/d为HR 1.12。
  • 每增加1 g/d ω-3脂肪酸剂量,房颤风险增加(HR 1.11,95%CI 1.06-1.15)。

核心结论

  • 在心血管结局随机对照试验中,补充海洋ω-3脂肪酸与房颤风险增加相关。
  • 该风险在测试>1 g/d剂量的试验中更大。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE和Embase 2012年1月1日至2020年12月31日文献及2019年发表的大型心血管RCT荟萃分析。
  • 纳入标准:海洋ω-3脂肪酸心血管结局RCT,报告房颤结果(预设结局、不良事件或住院原因),最低样本量500例,中位随访至少1年。
  • 排除专门研究ω-3脂肪酸短期效果对已确诊房颤或术后房颤复发影响的RCT。
  • 共筛查4049条记录,纳入7项研究,其中5项已在既往心血管RCT荟萃分析中。

主要发现

  • 荟萃分析显示使用海洋ω-3脂肪酸补充剂与房颤风险增加相关(n=2905;HR 1.25,95%CI 1.07-1.46;P=0.013)。
  • 按剂量分层,>1 g/d试验的HR为1.49(95%CI 1.04-2.15;P=0.042),≤1 g/d试验的HR为1.12(95%CI 1.03-1.22;P=0.024),交互作用P<0.001。
  • 荟萃回归显示ω-3脂肪酸剂量每增加1 g,房颤HR增加(HR 1.11,95%CI 1.06-1.15;P=0.001)。

临床怎么用

  • 在心血管结局试验背景下,处方海洋ω-3脂肪酸时应考虑房颤风险,尤其剂量>1 g/d时。
  • 对房颤高危患者,使用海洋ω-3脂肪酸需权衡获益与房颤风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Some, but not all, large-scale randomized controlled trials (RCTs) investigating the effects of marine ɷ-3 fatty acids supplementation on cardiovascular outcomes have reported increased risks of atrial fibrillation (AF). The potential reasons for disparate findings may be dose-related. METHODS: The MEDLINE and Embase databases were searched for articles and abstracts published between January 1, 2012, and December 31, 2020, in addition to a meta-analysis of large cardiovascular RCTs published in 2019. RCTs of cardiovascular outcomes of marine ɷ-3 fatty acids that reported results for AF, either as a prespecified outcome, an adverse event, or a cause for hospitalization, with a minimum sample size of 500 patients and a median follow-up of at least 1 year were included. RCTs specifically examining shorter-term effects of ɷ-3 fatty acids on recurrent AF in patients with established AF or postoperative AF were not included. The hazard ratio (HR) for the reported AF outcomes within each trial was meta-analyzed using random effects model with Knapp-Hartung adjustment and evaluated a dose-response relationship with a meta-regression model. RESULTS: Of 4049 screened records, 7 studies were included in the meta-analysis. Of those, 5 were already detected in a previous meta-analysis of cardiovascular RCTs. Among the 81 210 patients from 7 trials, 58 939 (72.6%) were enrolled in trials testing ≤1 g/d and 22 271 (27.4%) in trials testing >1 g/d of ɷ-3 fatty acids. The mean age was 65 years, and 31 842 (39%) were female. The weighted average follow-up was 4.9 years. In meta-analysis, the use of marine ɷ-3 fatty acid supplements was associated with an increased risk of AF (n=2905; HR, 1.25 [95% CI, 1.07-1.46]; P=0.013). In analyses stratified by dose, the HR was greater in the trials testing >1 g/d (HR, 1.49 [95% CI, 1.04-2.15]; P=0.042) compared with those testing ≤1 g/d (HR, 1.12 [95% CI, 1.03-1.22]; P=0.024; P for interaction <0.001). In meta-regression, the HR for AF increased per 1 g higher dosage of ɷ-3 fatty acids dosage (HR, 1.11 [95% CI, 1.06-1.15]; P=0.001). CONCLUSIONS: In RCTs examining cardiovascular outcomes, marine ɷ-3 supplementation was associated with an increased risk of AF. The risk appeared to be greater in trials testing >1 g/d.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Gencer B, Djousse L, Al-Ramady OT, et al. Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation. 2021. PMID: 34612056. doi:10.1161/CIRCULATIONAHA.121.055654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。